These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 16937107

  • 1. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T, Ohnishi K.
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
    [Abstract] [Full Text] [Related]

  • 2. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z, Zhou J, Lu X, Gong Z, Le XC.
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [Abstract] [Full Text] [Related]

  • 3. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
    Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, D'Andrea DM, Remick SC.
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):345-56. PubMed ID: 19911123
    [Abstract] [Full Text] [Related]

  • 4. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
    Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL.
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Ni J, Chen G, Shen Z, Li X, Liu H, Huang Y, Fang Z, Chen S, Wang Z, Chen Z.
    Chin Med J (Engl); 1998 Dec; 111(12):1107-10. PubMed ID: 11263375
    [Abstract] [Full Text] [Related]

  • 6. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U.
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [Abstract] [Full Text] [Related]

  • 7. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [Abstract] [Full Text] [Related]

  • 8. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H.
    J Clin Oncol; 2003 Jun 15; 21(12):2326-34. PubMed ID: 12805334
    [Abstract] [Full Text] [Related]

  • 9. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
    Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M.
    J Clin Oncol; 2010 Aug 20; 28(24):3866-71. PubMed ID: 20644086
    [Abstract] [Full Text] [Related]

  • 10. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
    Yoshino Y, Yuan B, Miyashita SI, Iriyama N, Horikoshi A, Shikino O, Toyoda H, Kaise T.
    Anal Bioanal Chem; 2009 Jan 20; 393(2):689-97. PubMed ID: 19009285
    [Abstract] [Full Text] [Related]

  • 11. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
    Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW, Kwong YL.
    Eur J Clin Pharmacol; 2002 Nov 20; 58(8):521-6. PubMed ID: 12451429
    [Abstract] [Full Text] [Related]

  • 12. Arsenic metabolism in multiple myeloma and astrocytoma cells.
    Falnoga I, Slejkovec Z, Pucer A, Podgornik H, Tusek-Znidaric M.
    Biol Trace Elem Res; 2007 Apr 20; 116(1):5-28. PubMed ID: 17634624
    [Abstract] [Full Text] [Related]

  • 13. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M, Wang B, Liu S, Wang W, Gao C, Hu S, Fan S, Hai X, Zhou J.
    Expert Rev Clin Pharmacol; 2019 Apr 20; 12(4):371-378. PubMed ID: 30795697
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
    Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S.
    Biol Pharm Bull; 2006 May 20; 29(5):1022-7. PubMed ID: 16651738
    [Abstract] [Full Text] [Related]

  • 15. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z, Song Y, Yuan CJ, Yang Y, Liu Z, Cai L.
    Hematol Oncol; 2004 Jun 20; 22(2):63-71. PubMed ID: 15468344
    [Abstract] [Full Text] [Related]

  • 16. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Cui W, Wang J, Nie RM, Zhao LL, Gao MQ, Zhu HM, Chen L, Hu J, Li JM, Shen ZX, Wang ZY, Chen SJ, Chen Z, Wang KK, Xi XD, Mi JQ.
    Eur J Haematol; 2018 Apr 20; 100(4):344-350. PubMed ID: 29266395
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H, Ohyashiki K.
    Leuk Res; 2010 Mar 20; 34(3):403-5. PubMed ID: 19733394
    [Abstract] [Full Text] [Related]

  • 20. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
    Zhang Z, Chen Y, Meng H, Sui M, Zhou Q, Shi C, Han L, Wang H, Zhou J.
    Leuk Lymphoma; 2013 Sep 20; 54(9):2041-6. PubMed ID: 23343178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.